bestatin
inhibitor
leucin
aminopeptidas
lapas
significantli
decreas
hiv
infect
reflect
reduc
number
posit
immunofluoresc
cell
level
revers
transcriptas
activ
number
provir
copi
found
bestatintr
cell
cellular
extracellular
lapas
activ
infect
cell
higher
lapas
activ
found
uninfect
cell
howev
cellular
extracellular
lapas
activ
well
total
protein
kinas
c
activ
lower
bestatintr
cell
convers
incub
human
lymphocyt
cell
lapas
promot
hiv
infect
possibl
role
lapas
pathophysiolog
hiv
assess
determin
lapas
serum
level
hiv
infect
patient
lapas
activ
level
three
order
magnitud
greater
sera
obtain
hiv
patient
detect
sera
uninfect
individu
although
bestatin
reduc
hiv
infect
moder
decreas
revers
transcriptas
activ
chronicallyinfect
human
tlymphocyt
cell
observ
base
higher
level
lapas
present
serum
hiv
patient
combin
inhibitori
effect
bestatin
lapas
protein
kinas
c
activ
suggest
lapas
may
play
import
role
earli
event
hiv
infect
viral
entri
elsevi
scienc
bv
aminopeptidas
compris
famili
zinc
metalloproteinas
catalyz
remov
elsevi
scienc
bv
right
reserv
pii
ntermin
amino
acid
residu
variou
protein
substrat
bestatin
leucin
isol
cultur
filtrat
streptomyc
umezawa
et
al
potent
slowbind
inhibitor
k
lapas
ec
variou
interest
immunomodulatori
properti
although
bestatin
effect
inhibit
aminopeptidas
aminopeptidas
b
lesser
extent
arginin
aminopeptidas
possess
high
specif
lapas
ec
form
tetrahedr
intermedi
within
activ
site
enzym
burley
et
al
contrast
membranebound
aminopeptidas
ec
refer
aminopeptidasen
put
receptor
coronavirus
delma
et
al
delma
et
al
yeager
et
al
significantli
less
inhibit
bestatin
k
show
distinct
inhibit
kinet
rich
et
al
wilk
prescott
kinet
differ
explain
base
differ
amino
acid
sequenc
encompass
activ
site
enzym
burley
et
al
rogi
et
al
treatment
human
lymphocyt
bestatin
increas
nk
activ
cell
possibl
also
lectindepend
cellular
cytotox
blomgren
et
al
well
phagocyt
activ
human
granulocyt
monocyt
jarstrand
blomgren
base
immunopotenti
properti
ascrib
bestatin
hord
et
al
perform
doubl
blind
clinic
studi
small
number
hiv
homosexu
men
group
notic
benefit
upon
bestatin
treatment
term
overal
immun
respons
howev
direct
effect
patient
viral
load
analyz
previous
report
bestatinmedi
inhibit
cellular
lapas
decreas
vitro
level
infect
tlymphocyt
cell
pulidocejudo
et
al
studi
character
effect
bestatin
possibl
role
lapas
hiv
infect
briefli
human
tlymphocyt
cell
line
infect
vitro
htlv
iiib
effect
compar
uninfect
chronic
infect
human
tlymphocyt
cell
report
inhibitori
effect
bestatin
possibl
role
lapas
hiv
infect
document
twelv
hour
prior
infect
htlv
iiib
cell
incub
viral
cultur
medium
alon
presenc
variou
concentr
bestatin
vgml
indic
case
chronicallyinfect
cell
bestatin
ad
time
concentr
use
cell
prior
use
bestatin
sigma
st
loui
mo
resuspend
rpmi
concentr
mgml
continu
presenc
bestatin
exponenti
grow
cell
subsequ
infect
htlv
iiib
viru
obtain
filter
cell
supernat
use
vm
filter
nalgen
rochest
ny
briefli
cell
pellet
cell
resuspend
ml
rpmi
alon
contain
htlv
iiib
revers
transcriptas
level
cpmml
infect
carri
h
constant
agit
final
volum
ml
chronicallyinfect
vitroinfect
human
tlymphocyt
cell
subsequ
wash
salin
phosphat
buffer
solut
pb
seed
densiti
cellsml
rpmi
supplement
fb
uml
penicillin
vgml
streptomycin
plate
syncytium
format
evalu
light
microscopi
day
variou
time
point
cell
select
well
subject
psoralenultraviolet
light
inactiv
watson
et
al
airdri
fix
glass
plate
cold
aceton
indirect
immunofluoresc
stain
perform
use
modif
standard
procedur
johnson
nogueira
araujo
aldovini
walker
plate
incub
min
block
buffer
pb
goat
serum
react
either
control
mous
serum
gag
monoclon
antibodi
olympu
immunochem
dilut
block
buffer
min
room
temperatur
cell
wash
three
time
pb
incub
min
goat
antimousefitc
antibodi
beckton
dickinson
slide
mount
paraphenylen
diamineglycerol
johnson
nogueira
araujo
fluoresc
cell
count
lapas
obtain
boehring
mannheim
purifi
gel
permeat
hplc
use
biosil
column
mm
biorad
equilibr
pb
cell
incub
purifi
lapas
uml
begin
h
prior
hiv
infect
effect
lapas
hiv
infect
follow
determin
level
syncytium
format
antigen
quantit
use
commerci
elisa
kit
antigen
captur
elisa
abbott
diagnost
divis
accord
instruct
provid
manufactur
thirtytwo
patient
divid
two
group
hiv
infect
noninfect
control
group
accord
absolut
cd
cell
count
peripher
blood
mononuclear
cell
pbmc
provir
load
determin
pcr
conway
et
al
cellular
extracellular
lapas
activ
determin
fluorometr
use
leucineinaphthylamid
substrat
kuramochi
et
al
reaction
stop
boil
sampl
min
follow
centrifug
g
min
valu
obtain
repres
averag
lapas
activ
determin
triplic
uninfect
control
hivinfect
subject
latter
group
divid
function
circul
provir
load
determin
quantit
pcr
conway
et
al
cell
seed
densiti
cellsml
rpmi
fb
uml
penicillin
vgml
streptomycin
presenc
absenc
bestatin
vgml
medium
chang
everi
third
day
cell
viabil
determin
trypan
blue
dye
exclus
thymidin
incorpor
also
measur
noma
et
al
duplic
cultur
day
prior
infect
cell
wash
three
time
pb
cell
viabil
determin
infect
perform
describ
indic
time
interv
ml
aliquot
cell
supernat
taken
spun
g
min
follow
polyethylen
glycol
precipit
fiscu
et
al
singlyinfect
chronic
infect
tlymphocyt
cell
line
analyz
revers
transcriptas
activ
briefli
antigen
quantit
use
commerci
elisa
kit
antigen
captur
elisa
abbott
diagnost
divis
follow
instruct
manufactur
sampl
assay
revers
transcriptas
activ
previous
describ
castro
et
al
cell
infect
htlv
iiib
without
pretreat
bestatin
vgml
maintain
cultur
day
without
infect
presenc
absenc
bestatin
day
postinfect
ml
aliquot
cell
suspens
taken
spun
g
min
supernat
remov
extracellular
lapas
activ
determin
kuramochi
et
al
cell
pellet
wash
three
time
pb
resuspend
vl
hank
solut
lapas
cellular
activ
also
determin
describ
kuramochi
et
al
total
pkc
activ
cell
estim
describ
elsewher
slack
proulx
duplic
cell
pellet
twelv
hour
prior
infect
cell
incub
viral
cultur
medium
alon
presenc
variou
concentr
bestatin
vgml
follow
infect
cell
maintain
cultur
day
time
period
cell
viabil
thymidin
incorpor
uninfect
control
bestatintreateduninfect
cell
found
unchang
addit
analyz
cd
cell
surfac
express
flow
cytometri
signific
chang
percentag
cd
gate
cell
experiment
condit
henc
day
exposur
bestatin
vgml
significantli
alter
cell
viabil
prolifer
cd
cell
surfac
express
cell
concentr
test
respect
effect
bestatin
hiv
infect
cell
bestatin
decreas
revers
transcriptas
activ
level
dosedepend
fashion
day
postinfect
reach
maximum
effect
concentr
vgml
bestatin
fig
found
maximun
inhibit
occur
cell
incu
bate
minimum
h
bestatin
prior
infect
cell
treat
bestatin
vgml
also
show
less
cytopath
effect
determin
number
syncytiawel
well
size
number
posit
cell
follow
immunofluoresc
stain
tabl
number
provir
copi
bestatintr
cell
also
significantli
lower
compar
infect
cell
alon
tabl
base
level
fig
revers
transcriptas
activ
fig
measur
control
bestatin
treat
cell
dose
depend
decreas
infect
cell
observ
start
day
postinfect
contrast
revers
transcriptas
activ
chronicallyinfect
cell
treat
bestatin
show
moder
decreas
less
control
day
treatment
fig
direct
effect
bestatin
cellular
aminopeptidas
activ
infect
control
cell
confirm
measur
lapas
activ
whole
intact
cell
cell
supernat
fig
interestingli
cellular
extracellular
lapas
activ
hiv
infect
cell
fig
higher
lapas
activ
detect
uninfect
control
cell
fig
howev
consist
lapas
inhibitori
properti
bestatin
case
cellular
extracellular
enzym
activ
lapas
found
bestatintr
cell
significantli
lower
untreatedcontrol
cell
fig
b
view
immunomodulatori
properti
ascrib
bestatin
blomgren
et
al
jarstrand
blomgren
cytokin
depend
pkcmediat
increas
express
hiv
kinter
et
al
pkc
activ
also
measur
substanti
decreas
pkc
activ
fig
observ
bestatintr
cell
parallel
decreas
lapas
activ
suggest
combin
inhibitori
tabl
effect
bestatin
provir
copi
cell
incub
bestatin
prior
infect
inactiv
number
provir
copi
determin
use
quantit
pcr
assay
describ
conway
et
al
data
express
mean
sd
n
cell
treatment
bestatin
day
incub
affect
cell
surviv
thymidin
incorpor
percent
cell
comparison
untreat
cell
effect
bestatin
lead
signific
decreas
hiv
infect
like
parallel
inhibit
lapas
protein
kinas
c
account
inhibit
hiv
infect
cell
thu
effect
exogen
ad
purifi
lapas
hiv
infect
studi
tabl
effect
lapas
hiv
infect
present
cell
treat
lapas
follow
hiv
infect
suscept
hiv
infect
show
higher
syncytia
number
extracellular
level
collect
result
suggest
cellular
extracellular
lapas
activ
potenti
infect
relev
lapas
activ
pathophysiolog
hiv
sustain
circul
serum
lapas
activ
level
found
hiv
infect
patient
serum
lapas
activ
level
shown
tabl
overal
increas
lapas
activ
infect
individu
observ
patient
eight
provir
cell
pbmc
appear
proport
circul
provir
load
howev
increas
close
four
order
magnitud
greater
uninfect
control
popul
result
present
studi
show
bestatin
competit
inhibitor
lapas
hinder
hiv
infect
antivir
effect
bestatin
seem
correl
decreas
lapas
pkc
activ
follow
h
preincub
period
prior
infect
regard
kinter
et
al
shown
cytokinemedi
activ
pkc
enhanc
hiv
express
chronic
infect
promonocyt
cell
henc
possibl
concurr
inhibit
lapas
pkc
bestatin
account
inhibit
hiv
infect
newli
infect
chronic
infect
cell
potenti
dual
mechan
bestatinmedi
inhibit
prompt
us
analyz
effect
exogen
ad
purifi
lapas
hiv
infect
experi
demonstr
lapasetr
cell
fact
prone
toward
hiv
infect
briefli
cell
show
higher
syncytia
number
extracellular
level
pretreat
incub
lapas
follow
hiv
infect
compar
cell
infect
alon
taken
togeth
result
suggest
cellular
extracellular
lapas
exopepti
fig
bestatinmedi
inhibit
lap
pkc
activ
infect
noninfect
cell
follow
infect
cell
steadi
increas
cellular
extracellular
lapas
activ
although
cellular
extracellular
lapas
activ
also
increas
noninfect
cell
b
increment
significantli
lower
howev
case
lapas
activ
significantli
decreas
presenc
bestatin
b
cell
incub
bestatin
also
show
signific
decreas
pkc
activ
otherwis
remain
constant
day
incub
c
although
data
stress
relev
lapas
exopeptidas
activ
hiv
infect
inhibitori
effect
bestatin
cellular
pkc
suggest
antivir
effect
bestatin
may
also
relat
earli
event
infect
viral
entri
cytokinemedi
upregul
hiv
replic
amount
lapas
activ
found
follow
hiv
infect
suggest
lapas
activ
may
use
surrog
marker
hiv
infect
studi
also
show
serum
lapas
activ
level
least
three
order
magnitud
greater
hivinfect
patient
low
eight
provir
pbmc
normal
healthi
individu
observ
reinforc
implic
lapas
key
cellular
enzym
involv
pathogenesi
hiv
exact
mechan
bestatinmedi
inhibit
hiv
infect
requir
consider
direct
effect
viruscel
fusion
revers
trancriptas
proteas
activ
studi
provid
evid
support
possibl
role
cellular
lapas
earli
event
hiv
infect
recent
suggest
follow
requir
cleavag
envelop
precursor
glycoprotein
env
promot
viralinduc
cell
fusion
cellularmedi
proteolyt
process
loop
novel
site
locat
within
carboxyl
terminu
take
place
rodriguez
et
al
suggest
lapas
exopeptidas
activ
may
involv
cellular
process
env
viru
cell
cell
cell
fusion
incub
cell
lap
uml
h
infect
caus
twofold
increas
level
well
number
syncytiawel
found
infect
cell
alon
suggest
increas
prone
hiv
infect
addit
lap
affect
cell
viabil
averag
viabil
cell
incub
lap
uml
day
without
infect
n
studi
also
provid
strong
rational
design
futur
studi
pertain
valid
serum
lapas
activ
surrog
marker
hiv
infect
respons
chemotherapi
well
test
effect
bestatin
first
cours
combin
chemotherapeut
protocol
phase
phase
trial
accord
previou
report
effect
bestatin
hivinfect
pulidocejudo
et
al
report
provid
evid
emphas
role
lapas
pkc
earli
event
infect
demonstr
actual
number
hiv
provir
copi
decreas
vitro
infect
cell
incub
bestatin
although
bestatin
also
shown
possess
vitro
antivir
activ
lymphocyt
cocultur
experi
bourinbaiar
et
al
date
potenti
clinic
applic
bestatin
alon
combin
therapi
remain
larg
unexplor
hord
et
al
clinic
benefit
bestatin
combin
therapi
current
investig
one
unit
lapas
defin
amount
enzym
requir
hydrolyz
vmol
lleucinei
naphthylamid
lleucin
inaphthylamid
per
min
ph
